Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $2.7600 (1.47%) ($2.7600 - $2.7600) on Mon. Feb. 7, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.33% (three month average) | RSI | 44 | Latest Price | $2.7600(1.47%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.1% a day on average for past five trading days. | Weekly Trend | HTBX advances 0.5% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) EEM(57%) IPO(57%) VWO(57%) BLOK(56%) IBUY(56%) | Factors Impacting HTBX price | HTBX will decline at least -2.165% in a week (0% probabilities). VXX(-49%) VIXM(-48%) UUP(-30%) USO(-4%) TBT(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.165% (StdDev 4.33%) | Hourly BBV | 0.6 () | Intraday Trend | 0% | | | |
|
Resistance Level | $2.83 | 5 Day Moving Average | $2.79(-1.08%) | 10 Day Moving Average | $2.74(0.73%) | 20 Day Moving Average | $2.83(-2.47%) | To recent high | -48.4% | To recent low | 10.4% | Market Cap | $304m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |